PTGX cites approvals and partnerships; $300 million share repurchase
PTGX says two recently approved drugs with strong phase III data are driving revenue, enabling a $300 million share repurchase. The pipeline targets oral peptide therapeutics, with assets advancing in I&I, obesity and rare diseases.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.